You are here

Borislav Dejanovic


Wu T, Dejanovic B, Gandham V, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 2019;28(8):2111-2123.e6.

Dejanovic B, Huntley MA, Mazière De A, et al. Changes in the synaptic proteome in tauopathy and rescue of Tau-induced synapse loss by C1q antibodies. Neuron. 2018;100(6):1322-1336.

Dejanovic B, Djémié T, Grünewald N, et al. Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. EMBO Mol Med. 2015;7(12):1580-1594.

Borislav Dejanovic, Ph.D.

Borislav Dejanovic is a group leader/staff scientist in the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, working under the direction of Morgan Sheng on the molecular mechanisms of neurodegenerative and psychiatric diseases. His team is particularly interested in the complement system, part of the innate immunity, and the role it plays in neuronal damage and neuroinflammation. In collaboration with groups from the Stanley Center and the Center for the Development of Therapeutics (CDoT), the team is working on new therapeutic approaches for psychiatric and neurodegenerative diseases.

Dejanovic joined the Broad Institute in May 2019 after completing his postdoctoral research in the neuroscience department at Genentech in South San Francisco, California. He holds a Ph.D. in biochemistry from the University of Cologne, Germany.

Contact Borislav Dejanovic via email at

January 2021